Radius Health (RDUS) PT Raised to $52 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Radius Health (RDUS) PT Raised to $45 at Jefferies
December 23, 2014 8:05 AM ESTJefferies analyst Eun Yang boosted his price target on Buy-rated Radius Health (NASDAQ: RDUS) to $45.00 (from $26.00) after as successful Phase 4 for Abaloparatide-SC.
Yang commented, "Ph3 for ABL in osteoporosis hit all endpoints of study for regulatory approval & for potential advantages (vs. Forteo, $1.25B in... More
Radius Health (RDUS) Reports Positive Top-Line Abaloparatide-SC Phase 3 Data
December 22, 2014 6:42 AM ESTRadius Health (Nasdaq: RDUS) announced positive top-line 18-month fracture results from the Company's Phase 3 clinical trial (ACTIVE) evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.
On the primary endpoint, the investigational drug abaloparatide-SC (n=690, fracture rate 0.72%) achieved a statistically significant 83% reduction of incident vertebral fractures as compared to the placebo-treated group (n=711, fracture rate 4.36%)... More
